Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Yearbook of Endocrinology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0084-3741(08)79098-X
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

  2007cited by this paper
• Assessment of compliance with osteoporosis treatment and its consequences in a managed care population.

  2006cited by this paper
• Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.

  2006cited by this paper
• Persistence with weekly alendronate therapy among postmenopausal women

  2006cited by this paper
• Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis*

  2005cited by this paper
• Intravenous zoledronic acid in postmenopausal women with low bone mineral density.

  2002cited by this paper

• Denosumab for prevention of immobilization-induced alterations of bone turnover in patients admitted to a neurosurgical intensive care unit: a randomized controlled trial

  2022cites this paper
• Implementation of a clinical pathway for osteoporosis management within an Orthopaedic Fracture Clinic

  2022cites this paper
• Aspects of fracture prevention The role of fracture liaison services and alendronate

  2020cites this paper
• The treatment gap: the missed opportunities for osteoporosis therapy.

  2020cites this paper
• Automated quantitative morphometry of vertebral heights on spinal radiographs: comparison of a clinical workflow tool with standard 6-point morphometry

  2019cites this paper
• Aminobisphosphonate‐associated orbital and ocular inflammatory disease

  2019influential citation
• Material properties of bone in the femoral head treated with ibandronate and BMP‐2 following ischemic osteonecrosis

  2017cites this paper
• Emerging anabolic agents in the treatment of osteoporosis

  2017cites this paper
• Atypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and Prevention

  2016cites this paper
• Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

  2016cites this paper
• Effect of zoledronic acid on spinal fusion outcomes in an ovariectomized rat model of osteoporosis

  2015cites this paper
• Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

  2015cites this paper
• Caso clínico a debate: vacaciones terapéuticas, ¿sí o no?

  2014cites this paper
• Intravenous Treatment With Ibandronate Normalizes Bone Matrix Mineralization and Reduces Cortical Porosity After Two Years in Male Osteoporosis: A Paired Biopsy Study

  2014cites this paper
• Effect of ONO‐5334 on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Osteoporosis: 2‐Year Results From the OCEAN Study

  2014cites this paper
• Effects of bisphosphonate treatment on DNA methylation in osteonecrosis of the jaw.

  2013cites this paper
• Bisphosphonates: Focus on Inflammation and Bone Loss

  2012cites this paper
• Pharmacodynamic Effects on Biochemical Markers of Bone Turnover and Pharmacokinetics of the Cathepsin K Inhibitor, ONO‐5334, in an Ascending Multiple‐Dose, Phase 1 Study

  2012cites this paper
• Osteoporosis as a risk factor for distal radial fractures: a case-control study.

  2011cites this paper
• Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease

  2010cites this paper
• How to prevent glucocorticoid-induced osteoporosis

  2010cites this paper
• Should Know Osteoporosis Disease Management: What Every Orthopaedic Surgeon

  2009cites this paper
• Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States

  2009influential citation
• Role of sport and exercise in the maintenance of female bone health

  2009cites this paper
• Short-Term Effects of High-Dose Zoledronic Acid Treatment on Bone Mineralization Density Distribution After Orthotopic Liver Transplantation

  2008cites this paper
• Utility of Biochemical Markers of Bone Turnover and Bone Mineral Density in Management of Osteoporosis

  2008cites this paper
• Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss

  2008cites this paper
• Drug, Healthcare and Patient Safety Dovepress Safety and Tolerability of Zoledronic Acid and Other Bisphosphonates in Osteoporosis Management

  year unknowncites this paper